Type IIB von Willebrand Disease (vWD) is characterized by the selective loss of large von Willebrand Factor (vWF) multimers from plasma, presumably due to their increased reactivity with platelets and subsequent clearance from the circulation. Using the
. Type IIB vWD is additionally characterized by enhanced ristocetin-induced platelet aggregation (RIPA) and increased binding ofthe abnormal vWF to normal platelets (3, 4) . Clinically, Type IIB vWD is associated with a bleeding disorder of variable severity and thrombocytopenia which is often exacerbated by pregnancy (5, 6) , stress (7), advanced age (8) , or 1-deamino-8-D-arginine-vasopressin (DDAVP) (9) . The latter, the treatment of choice for many forms of vWD, is relatively contraindicated in Type IIB (9) .
Patients with Type IIB vWD specifically lack the largest multimers of vWF in plasma but not in platelets. It has been hypothesized that plasma high molecular weight vWF multimers of patients with Type IIB vWD bind spontaneously to platelets and are subsequently cleared from the circulation (10) , accounting for both the characteristic vWF multimer pattern and the frequently associated thrombocytopenia. In support ofthis hypothesis, vWF secreted by Type IIB vWD umbilical vein endothelial cells were shown to contain the full range of vWF multimers on gel analysis and to induce spontaneous platelet aggregation in vitro (I 1). The human vWF gene has been localized to the short arm of chromosome 12 (12) and spans 178 kb interrupted by 51 introns (13) . In addition, a nonprocessed pseudogene highly homologous to the mid-portion of vWF has been identified on human chromosome 22 (14) . vWF is synthesized by endothelial cells and megakaryocytes and undergoes extensive posttranslational processing including multimerization prior to secretion (15) . The 2813 residue vWF amino acid sequence consists of multiple repeated segments, including the triplicated A domains (16, 17) . A region important for the interaction of vWF with platelet glycoprotein lb (GpIb), one of the primary receptors for vWF on platelets, has been localized to the vWF Al domain between amino acids 449 and 728 of the mature protein (18) . This region also contains binding sites for heparin (19) and collagen (20, 21) . The enhanced platelet aggregation induced by vWF prepared from a patient with Type IIB vWD can be blocked by a monoclonal antibody directed against GpIb (3, 22) . Furthermore, the tryptic fragment of normal vWF containing the GpIb binding domain (amino acids 449-728) was shown to block spontaneous platelet aggregation in patients with the Tampa variant of Type IIB vWD (23) .
Over the past several years, molecular defects responsible for several types of vWD have been identified. Large gene deletions appear to be an uncommon mechanism for vWD, seen primarily in patients with inhibitors to vWF (14, 24, 25) . Missense mutations within the vWF A2 domain were recently identified in two patients with Type IIA vWD (26) and additional Type 11A patients may demonstrate other mutations in the same region (27) . We now report the identification of four distinct potential vWF missense mutations occurring in 14 patients from 11 unrelated Type I1B vWD families. These substitutions are all contained in a 36-amino acid segment within the putative GpIb binding domain of vWF.
Methods
Patient material. 14 patients with Type IIB vWD from 11 unrelated families were studied (B [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The family of patient B14 has been previously reported (7) . The father of B6 has also been reported (3). Patients were classified by referring physicians as having Type IIB vWD if they had a moderately severe bleeding disorder characterized by some or all of the following clinical features: thrombocytopenia, prolonged bleeding time, normal to low factor VIII procoagulant activity, normal to low vWF antigen, low plasma ristocetin cofactor activity, decreased circulating high molecular weight vWF multimers with intact platelet vWF multimers, enhanced RIPA at a low concentration of ristocetin (0.2-0.6 mg/ml), and the absence of platelet aggregation or agglutination when normal purified vWF or cryoprecipitate is added to patient platelet rich plasma. Genomic DNA was prepared from peripheral blood leukocytes by standard methods (12) . Genomic DNA was also obtained from 67 normal individuals with no prior history of bleeding disorders. The umbilical cord from a patient with Type IIB vWD was also obtained and a human umbilical vein endothelial cell culture was prepared (28) . DNA was isolated from the cultured cells and is included in subsequent analysis as B5. Clinical laboratory data obtained from the child are consistent with the diagnosis of Type IIB vWD.
DNA sequence analysis. The PCR was used to amplify vWF exon 28 sequences as previously described (26) . Nucleotide position numbering is per the sequence of Bonthron, et al. (29) , with the J"A" of the initiator "ATG" codon taken as + (26) . Mutations first identified in pooled sequence (B3) were confirmed by analysis of individual clones. DNA from patient B6 was analyzed from nucleotide 3820 to 4120 by direct sequence of PCR products using asymmetric PCR (32) as previously described (33) . The mutations identified by allele-specific oligonucleotide (ASO) or restriction digest for patients B2, B4, B5, B7, B8, B9, B10, Bl 1, B12, and B14 were all confirmed by asymmetric PCR sequencing.
Asymmetric PCR was performed with replinase (New England Nuclear, Bannockburn, IL).
Restriction analysis and allele-specific oligonucleotide hybridization. Cellular DNA was amplified by PCR using primers A and B, as described above. The C3922-IT and G4022-*PA substitutions both result in convenient restriction site changes, loss of an Hha I site and gain ofa Pst I site, respectively. For analysis ofthese substitutions, PCR products were digested with Hha I or Pst I (Bethesda Research Laboratories, Gaithersburg, MD) and analyzed by fractionation on an ethidium bromide-stained 4% composite agarose gel (3% NuSieve agarose [FMC BioProducts, Rockland ME] and 1% standard agarose [Bethesda Research Laboratories]). The remaining substitutions were evaluated by dot blot analysis and ASO hybridization, as previously described (34). 1 5-mer oligonucleotides were synthesized with either normal (underlined) or "mutant" (shown in parentheses) sequence in the 8th position. Probes 1 and 2: GATGGAGC(T)GGCTGCG; probes 3 and 4: GGTCCGCG(A)TGGCCGT; probes 5 and 6: TTTGTCCG-(A)CTACGTC. Probes 2, 4, and 6 are the "mutant" oligonucleotides corresponding, respectively, to the normal sequences of probes 1, 3, and 5 (see Fig. 1 ). 3 MAl of PCR product were denatured in 200 Ml of0.4 N sodium hydroxide, 25 mM EDTA, and applied to a nylon filter (Hybond-N; Amersham Corp., Arlington Heights, IL) using a dot blot apparatus (Hybri -dot; Bethesda Research Laboratories). Filters were hybridized with end-labeled oligonucleotides with the final wash performed in 5x SSPE and 0.1% SDS for 10 min at an optimal temperature empirically determined for each ASO probe.
Results
Exon 28 sequence in patient BJ. B Lyons, D. Ginsburg, manuscript in preparation). Individual Ml 3 exon 28 PCR clones were typed for this restriction fragment length polymorphism (RFLP) and the inserts from two independent clones for each allele were sequenced in their entirety. In this way authentic sequence differences, which should be present in both clones of the same allele, could be distinguished from PCR errors, which should be present in only one clone. Only normal sequence was observed on the Bst Eli (-) allele, whereas two novel changes, both resulting in amino acid substitutions, were identified on the Bst Eli (+) allele: a C-o.T transition at cDNA nucleotide 3916 resulting in an Arg543--.Trp substitution (Fig. 2 A) Fig. 3 A, B) . B4 is the mother of B5. Direct DNA sequence analysis by asymmetric PCR confirmed the ASO genotype data.
Identification ofa secondpotential Type IIB vWD mutation at nucleotide 3946. For B 12 DNA, sequence analysis was performed for both pooled and individual M 13 clones as described above. A single change, a G-INA transition at nucleotide 3946, was identified in one allele, resulting in a Val553-*oMet substitution (Fig. 2 B) . The same potential missense mutation was detected by dot blot analysis and ASO hybridization, using ASO probes 3 and 4 in the patient's affected son (B 13) and in two other unrelated Type IIB vWD patients (B2 and B8; Fig.  4 ), but was not detected in any of 98 normal alleles screened (data not shown). The ASO data were confirmed by direct DNA sequence analysis of the PCR products, as described above.
Identification ofa third potential Type IIB vWD mutation at nucleotide 3922. B3 DNA was amplified with primers A and C and the resulting PCR products sequenced as a pool of M 13 clones. A single substitution, a C-T transition at nucleotide 3922 was identified and confirmed by sequence analysis ofindividual M 13 clones (Fig. 5 A) . This change, which results in an Arg545-*Cys substitution, destroys an Hha I restriction site and thus can be detected by PCR and restriction enzyme digestion (Fig. 5 B) . By this analysis, patients B7, B (26, 27) . The Type 1IB vWD phenotype is associated with a loss of large vWF multimers similar to that ofType IIA, but occurring through a unique mechanism related to an apparent increased affinity for the platelet vWF receptor GpIb (3, 11, 22, 23) . The vWF functional domain responsible for GpIb binding appears to reside between Val449 and Lys728 (18, 35) . Based on the hypothesis that missense mutations within this region might alter the vWF/GpIb interaction resulting in the Type hIB vWD phenotype, a portion of vWF exon 28, encoding Lys534-Pro921, was targeted for DNA sequence analysis. Four potential missense mutations, resulting in Arg543--.Trp, Arg545--fCys, Val553-*.Met, and Arg578-* Gln substitutions, were identified by this approach, each occurring in a different Type IIB vWD patient. The first three substitutions were subsequently detected by ASO hybridization analysis or restriction enzyme digestion in additional unrelated Type IIB vWD patients. For each of these three mutations, inheritance of the same sequence could also be traced to an affected offspring (B4 and B5 for Arg543--.Trp, BIO and B 1 for Arg545-Cys, and B12 and B13 for Val553-'Met). In total, the four identified mutations account for all 14 Type IIB vWD patients studied, derived from 11 unrelated families.
A rare DNA sequence polymorphism at nucleotide 4196 was identified in patient B 1, on the same allele as the candidate Arg543--CTrp mutation. The two other Arg543-.Trp patients were homozygous for the more common allele at position 4916. The association of this same substitution with at least [-]) strongly suggests that this particular mutation has arisen at least two independent times. The occurrence of the Arg543--Trp substitution as at least two independent mutational events in three Type IIB patients, with its absence from the 134 normal chromosomes screened, provides compelling genetic evidence that this substitution represents an authentic Type IIB vWD mutation. The identification of three other amino acid substitutions in eight other Type IIB vWD families, all also within the vWF GpIb binding domain (see below), provides further evidence in support ofthis hypothesis, as does the appropriate inheritance of the mutant alleles in three affected offspring. Whether the Arg545-.Cys and Val553-*Met mutations arose via more than one independent mutational event and whether two or three independent events occurred among the Arg543--CTrp families must await more detailed vWF RFLP haplotype analysis. Of note, all four potential missense mutations reported here represent C-U~T transitions at CpG dinucleotides, proposed "hot spots" for mutation in the human genome (36) . None of these mutations are contained in vWF pseudogene sequence (Ginsburg, D., and M. Bruck, unpublished data).
All four mutations are contained in a 36 amino acid segment within the vWF tryptic fragment Val449-*Lys728, which has been shown to interact with platelet GpIb, heparin, and collagen (18) (19) (20) (21) 37 
